PINK
LZAGY

Lonza Group AG

Diagnostics & Research
Healthcare

Prices are adjusted according to historical splits.

Lonza Group AG Stock Price

Vitals

Today's Low:
$54.22
Today's High:
$54.9
Open Price:
$54.28
52W Low:
$44.1618
52W High:
$66
Prev. Close:
$54.11
Volume:
49947

Company Statistics

Market Cap.:
$40.69 billion
Book Value:
13.9257
Revenue TTM:
$6.32 billion
Operating Margin TTM:
21.21%
Gross Profit TTM:
$2.44 billion
Profit Margin:
17.93%
Return on Assets TTM:
4.87%
Return on Equity TTM:
11.06%

Company Profile

Lonza Group AG had its IPO on under the ticker symbol LZAGY.

The company operates in the Healthcare sector and Diagnostics & Research industry. Lonza Group AG has a staff strength of 17,896 employees.

Stock update

Shares of Lonza Group AG opened at $54.28 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $54.22 - $54.9, and closed at $54.69.

This is a +1.07% increase from the previous day's closing price.

A total volume of 49,947 shares were traded at the close of the day’s session.

In the last one week, shares of Lonza Group AG have slipped by -0.87%.

Lonza Group AG's Key Ratios

Lonza Group AG has a market cap of $40.69 billion, indicating a price to book ratio of 3.3755 and a price to sales ratio of 6.1944.

In the last 12-months Lonza Group AG’s revenue was $6.32 billion with a gross profit of $2.44 billion and an EBITDA of $1.86 billion. The EBITDA ratio measures Lonza Group AG's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Lonza Group AG’s operating margin was 21.21% while its return on assets stood at 4.87% with a return of equity of 11.06%.

In Q2, Lonza Group AG’s quarterly earnings growth was a negative -16.2% while revenue growth was a positive 3.2%.

Lonza Group AG’s PE and PEG Ratio

Forward PE
26.3158
Trailing PE
32.1706
PEG
1.5232

Its diluted EPS in the last 12-months stands at $1.7 per share while it has a forward price to earnings multiple of 26.3158 and a PEG multiple of 1.5232. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lonza Group AG’s profitability.

Lonza Group AG stock is trading at a EV to sales ratio of 6.1914 and a EV to EBITDA ratio of 32.0192. Its price to sales ratio in the trailing 12-months stood at 6.1944.

Lonza Group AG stock pays annual dividends of $3.5 per share, indicating a yield of 0.72% and a payout ratio of 23.3%.

Balance sheet and cash flow metrics

Total Assets
$17.67 billion
Total Liabilities
$2.71 billion
Operating Cash Flow
$-88500000.00
Capital Expenditure
$420.50 million
Dividend Payout Ratio
23.3%

Lonza Group AG ended 2024 with $17.67 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $17.67 billion while shareholder equity stood at $10.31 billion.

Lonza Group AG ended 2024 with $0 in deferred long-term liabilities, $2.71 billion in other current liabilities, 74000000.00 in common stock, $9.27 billion in retained earnings and $2.89 billion in goodwill. Its cash balance stood at $1.70 billion and cash and short-term investments were $2.15 billion. The company’s total short-term debt was $449,000,000 while long-term debt stood at $2.46 billion.

Lonza Group AG’s total current assets stands at $5.63 billion while long-term investments were $0 and short-term investments were $450.00 million. Its net receivables were $1.53 billion compared to accounts payable of $0 and inventory worth $1.93 billion.

In 2024, Lonza Group AG's operating cash flow was $-88500000.00 while its capital expenditure stood at $420.50 million.

Comparatively, Lonza Group AG paid $0.23 in dividends in 2024.

Other key metrics

Current Trading Price
$54.69
52-Week High
$66
52-Week Low
$44.1618
Analyst Target Price
$

Lonza Group AG stock is currently trading at $54.69 per share. It touched a 52-week high of $66 and a 52-week low of $66. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $57.08 and 200-day moving average was $57.77 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 9.4% are held by institutions.

Frequently Asked Questions About Lonza Group AG

The stock symbol (also called stock or share ticker) of Lonza Group AG is LZAGY

The IPO of Lonza Group AG took place on

Similar Industry Stocks (Diagnostics & Research)

Last Price
Chg
Chg%
$232.95
-5.55
-2.33%
$27.77
-0.16
-0.57%
Flex Ltd (FLEX)
$26.3
-0.2
-0.75%
$1.62
-0.06
-3.57%
$41.37
-1.79
-4.15%
$0.12
-0
-0.42%
$132.5
-10.05
-7.05%
$288.09
5.15
+1.82%
$20.45
-1.2
-5.54%
$2
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.

Address

Muenchensteinerstrasse 38, Basel, Switzerland, 4002